Global Antibody Drug Conjugates (ADCs) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 212169
  • calendar_today Published On: Apr, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Antibody Drug Conjugates (ADCs) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Antibody Drug Conjugates (ADCs) size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Antibody Drug Conjugates (ADCs) market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Antibody Drug Conjugates (ADCs) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Seattle Genetics Technology

ImmunoGen Technology

Immunomedics Technology

Market segment by Application, can be divided into

Hospital

Clinics

Others

Market segment by players, this report covers

Roche

Pfizer

Novartis

Genmab

Bayer

Seattle Genetics

Takeda Pharmaceuticals

AbbVie

AbGenomics

ADC Therapeutics

Astellas Pharma

Kairos Therapeutics

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Antibody Drug Conjugates (ADCs) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Antibody Drug Conjugates (ADCs), with revenue, gross margin and global market share of Antibody Drug Conjugates (ADCs) from 2019 to 2021.

Chapter 3, the Antibody Drug Conjugates (ADCs) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Antibody Drug Conjugates (ADCs) market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Antibody Drug Conjugates (ADCs) research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Antibody Drug Conjugates (ADCs)

1.2 Classification of Antibody Drug Conjugates (ADCs) by Type

1.2.1 Overview: Global Antibody Drug Conjugates (ADCs) Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type in 2020

1.2.3 Seattle Genetics Technology

1.2.4 ImmunoGen Technology

1.2.5 Immunomedics Technology

1.3 Global Antibody Drug Conjugates (ADCs) Market by Application

1.3.1 Overview: Global Antibody Drug Conjugates (ADCs) Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospital

1.3.3 Clinics

1.3.4 Others

1.4 Global Antibody Drug Conjugates (ADCs) Market Size & Forecast

1.5 Global Antibody Drug Conjugates (ADCs) Market Size and Forecast by Region

1.5.1 Global Antibody Drug Conjugates (ADCs) Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Antibody Drug Conjugates (ADCs) Market Size by Region, (2016-2021)

1.5.3 North America Antibody Drug Conjugates (ADCs) Market Size and Prospect (2016-2026)

1.5.4 Europe Antibody Drug Conjugates (ADCs) Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size and Prospect (2016-2026)

1.5.6 South America Antibody Drug Conjugates (ADCs) Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Antibody Drug Conjugates (ADCs) Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Antibody Drug Conjugates (ADCs) Market Drivers

1.6.2 Antibody Drug Conjugates (ADCs) Market Restraints

1.6.3 Antibody Drug Conjugates (ADCs) Trends Analysis

2 Company Profiles

2.1 Roche

2.1.1 Roche Details

2.1.2 Roche Major Business

2.1.3 Roche Antibody Drug Conjugates (ADCs) Product and Solutions

2.1.4 Roche Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Roche Recent Developments and Future Plans

2.2 Pfizer

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Antibody Drug Conjugates (ADCs) Product and Solutions

2.2.4 Pfizer Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Pfizer Recent Developments and Future Plans

2.3 Novartis

2.3.1 Novartis Details

2.3.2 Novartis Major Business

2.3.3 Novartis Antibody Drug Conjugates (ADCs) Product and Solutions

2.3.4 Novartis Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Novartis Recent Developments and Future Plans

2.4 Genmab

2.4.1 Genmab Details

2.4.2 Genmab Major Business

2.4.3 Genmab Antibody Drug Conjugates (ADCs) Product and Solutions

2.4.4 Genmab Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Genmab Recent Developments and Future Plans

2.5 Bayer

2.5.1 Bayer Details

2.5.2 Bayer Major Business

2.5.3 Bayer Antibody Drug Conjugates (ADCs) Product and Solutions

2.5.4 Bayer Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Bayer Recent Developments and Future Plans

2.6 Seattle Genetics

2.6.1 Seattle Genetics Details

2.6.2 Seattle Genetics Major Business

2.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Product and Solutions

2.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Seattle Genetics Recent Developments and Future Plans

2.7 Takeda Pharmaceuticals

2.7.1 Takeda Pharmaceuticals Details

2.7.2 Takeda Pharmaceuticals Major Business

2.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product and Solutions

2.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Takeda Pharmaceuticals Recent Developments and Future Plans

2.8 AbbVie

2.8.1 AbbVie Details

2.8.2 AbbVie Major Business

2.8.3 AbbVie Antibody Drug Conjugates (ADCs) Product and Solutions

2.8.4 AbbVie Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 AbbVie Recent Developments and Future Plans

2.9 AbGenomics

2.9.1 AbGenomics Details

2.9.2 AbGenomics Major Business

2.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Product and Solutions

2.9.4 AbGenomics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 AbGenomics Recent Developments and Future Plans

2.10 ADC Therapeutics

2.10.1 ADC Therapeutics Details

2.10.2 ADC Therapeutics Major Business

2.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions

2.10.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 ADC Therapeutics Recent Developments and Future Plans

2.11 Astellas Pharma

2.11.1 Astellas Pharma Details

2.11.2 Astellas Pharma Major Business

2.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Product and Solutions

2.11.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Astellas Pharma Recent Developments and Future Plans

2.12 Kairos Therapeutics

2.12.1 Kairos Therapeutics Details

2.12.2 Kairos Therapeutics Major Business

2.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions

2.12.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Kairos Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Antibody Drug Conjugates (ADCs) Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Antibody Drug Conjugates (ADCs) Players Market Share

3.2.2 Top 10 Antibody Drug Conjugates (ADCs) Players Market Share

3.2.3 Market Competition Trend

3.3 Antibody Drug Conjugates (ADCs) Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Antibody Drug Conjugates (ADCs) Revenue and Market Share by Type (2016-2021)

4.2 Global Antibody Drug Conjugates (ADCs) Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2016-2021)

5.2 Antibody Drug Conjugates (ADCs) Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2026)

6.2 North America Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2026)

6.3 North America Antibody Drug Conjugates (ADCs) Market Size by Country

6.3.1 North America Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2026)

6.3.2 United States Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

6.3.3 Canada Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

6.3.4 Mexico Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2026)

7.2 Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2026)

7.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Country

7.3.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2026)

7.3.2 Germany Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

7.3.3 France Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

7.3.5 Russia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

7.3.6 Italy Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2026)

8.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2026)

8.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region

8.3.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Region (2016-2026)

8.3.2 China Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

8.3.3 Japan Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

8.3.4 South Korea Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

8.3.5 India Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

8.3.7 Australia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2026)

9.2 South America Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2026)

9.3 South America Antibody Drug Conjugates (ADCs) Market Size by Country

9.3.1 South America Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2026)

9.3.2 Brazil Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

9.3.3 Argentina Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2026)

10.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2026)

10.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country

10.3.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2026)

10.3.2 Turkey Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

10.3.4 UAE Antibody Drug Conjugates (ADCs) Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Antibody Drug Conjugates (ADCs) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Antibody Drug Conjugates (ADCs) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Antibody Drug Conjugates (ADCs) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Region (2016-2021)

Table 5. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Region (2021-2026)

Table 6. Roche Corporate Information, Head Office, and Major Competitors

Table 7. Roche Major Business

Table 8. Roche Antibody Drug Conjugates (ADCs) Product and Solutions

Table 9. Roche Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Pfizer Corporate Information, Head Office, and Major Competitors

Table 11. Pfizer Major Business

Table 12. Pfizer Antibody Drug Conjugates (ADCs) Product and Solutions

Table 13. Pfizer Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Novartis Corporate Information, Head Office, and Major Competitors

Table 15. Novartis Major Business

Table 16. Novartis Antibody Drug Conjugates (ADCs) Product and Solutions

Table 17. Novartis Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Genmab Corporate Information, Head Office, and Major Competitors

Table 19. Genmab Major Business

Table 20. Genmab Antibody Drug Conjugates (ADCs) Product and Solutions

Table 21. Genmab Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Bayer Corporate Information, Head Office, and Major Competitors

Table 23. Bayer Major Business

Table 24. Bayer Antibody Drug Conjugates (ADCs) Product and Solutions

Table 25. Bayer Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Seattle Genetics Corporate Information, Head Office, and Major Competitors

Table 27. Seattle Genetics Major Business

Table 28. Seattle Genetics Antibody Drug Conjugates (ADCs) Product and Solutions

Table 29. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Takeda Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 31. Takeda Pharmaceuticals Major Business

Table 32. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product and Solutions

Table 33. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. AbbVie Corporate Information, Head Office, and Major Competitors

Table 35. AbbVie Major Business

Table 36. AbbVie Antibody Drug Conjugates (ADCs) Product and Solutions

Table 37. AbbVie Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. AbGenomics Corporate Information, Head Office, and Major Competitors

Table 39. AbGenomics Major Business

Table 40. AbGenomics Antibody Drug Conjugates (ADCs) Product and Solutions

Table 41. AbGenomics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. ADC Therapeutics Corporate Information, Head Office, and Major Competitors

Table 43. ADC Therapeutics Major Business

Table 44. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions

Table 45. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Astellas Pharma Corporate Information, Head Office, and Major Competitors

Table 47. Astellas Pharma Major Business

Table 48. Astellas Pharma Antibody Drug Conjugates (ADCs) Product and Solutions

Table 49. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Kairos Therapeutics Corporate Information, Head Office, and Major Competitors

Table 51. Kairos Therapeutics Major Business

Table 52. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions

Table 53. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Players (2019-2021)

Table 55. Global Antibody Drug Conjugates (ADCs) Revenue Share by Players (2019-2021)

Table 56. Breakdown of Antibody Drug Conjugates (ADCs) by Company Type (Tier 1, Tier 2 and Tier 3)

Table 57. Antibody Drug Conjugates (ADCs) Players Head Office, Products and Services Provided

Table 58. Antibody Drug Conjugates (ADCs) Mergers & Acquisitions in the Past Five Years

Table 59. Antibody Drug Conjugates (ADCs) New Entrants and Expansion Plans

Table 60. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Type (2016-2021)

Table 61. Global Antibody Drug Conjugates (ADCs) Revenue Share by Type (2016-2021)

Table 62. Global Antibody Drug Conjugates (ADCs) Revenue Forecast by Type (2021-2026)

Table 63. Global Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2021)

Table 64. Global Antibody Drug Conjugates (ADCs) Revenue Forecast by Application (2021-2026)

Table 65. North America Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2021) & (USD Million)

Table 66. North America Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (USD Million)

Table 67. North America Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2021) & (USD Million)

Table 68. North America Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (USD Million)

Table 69. North America Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2021) & (USD Million)

Table 70. North America Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026) & (USD Million)

Table 71. Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2021) & (USD Million)

Table 72. Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (USD Million)

Table 73. Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2021) & (USD Million)

Table 74. Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (USD Million)

Table 75. Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2021) & (USD Million)

Table 76. Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026) & (USD Million)

Table 77. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2021) & (USD Million)

Table 78. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (USD Million)

Table 79. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2021) & (USD Million)

Table 80. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (USD Million)

Table 81. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Region (2016-2021) & (USD Million)

Table 82. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Region (2021-2026) & (USD Million)

Table 83. South America Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2021) & (USD Million)

Table 84. South America Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (USD Million)

Table 85. South America Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2021) & (USD Million)

Table 86. South America Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (USD Million)

Table 87. South America Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2021) & (USD Million)

Table 88. South America Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026) & (USD Million)

Table 89. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Type (2016-2021) & (USD Million)

Table 90. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (USD Million)

Table 91. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Application (2016-2021) & (USD Million)

Table 92. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (USD Million)

Table 93. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Country (2016-2021) & (USD Million)

Table 94. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Antibody Drug Conjugates (ADCs) Picture

Figure 2. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type in 2020

Figure 3. Seattle Genetics Technology

Figure 4. ImmunoGen Technology

Figure 5. Immunomedics Technology

Figure 6. Antibody Drug Conjugates (ADCs) Revenue Market Share by Application in 2020

Figure 7. Hospital Picture

Figure 8. Clinics Picture

Figure 9. Others Picture

Figure 10. Global Antibody Drug Conjugates (ADCs) Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 11. Global Antibody Drug Conjugates (ADCs) Revenue and Forecast (2016-2026) & (USD Million)

Figure 12. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Region (2016-2026)

Figure 13. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Region in 2020

Figure 14. North America Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. Europe Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. South America Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Antibody Drug Conjugates (ADCs) Market Drivers

Figure 20. Antibody Drug Conjugates (ADCs) Market Restraints

Figure 21. Antibody Drug Conjugates (ADCs) Market Trends

Figure 22. Roche Recent Developments and Future Plans

Figure 23. Pfizer Recent Developments and Future Plans

Figure 24. Novartis Recent Developments and Future Plans

Figure 25. Genmab Recent Developments and Future Plans

Figure 26. Bayer Recent Developments and Future Plans

Figure 27. Seattle Genetics Recent Developments and Future Plans

Figure 28. Takeda Pharmaceuticals Recent Developments and Future Plans

Figure 29. AbbVie Recent Developments and Future Plans

Figure 30. AbGenomics Recent Developments and Future Plans

Figure 31. ADC Therapeutics Recent Developments and Future Plans

Figure 32. Astellas Pharma Recent Developments and Future Plans

Figure 33. Kairos Therapeutics Recent Developments and Future Plans

Figure 34. Global Antibody Drug Conjugates (ADCs) Revenue Share by Players in 2020

Figure 35. Antibody Drug Conjugates (ADCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 36. Global Top 3 Players Antibody Drug Conjugates (ADCs) Revenue Market Share in 2020

Figure 37. Global Top 10 Players Antibody Drug Conjugates (ADCs) Revenue Market Share in 2020

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 39. Global Antibody Drug Conjugates (ADCs) Revenue Share by Type in 2020

Figure 40. Global Antibody Drug Conjugates (ADCs) Market Share Forecast by Type (2021-2026)

Figure 41. Global Antibody Drug Conjugates (ADCs) Revenue Share by Application in 2020

Figure 42. Global Antibody Drug Conjugates (ADCs) Market Share Forecast by Application (2021-2026)

Figure 43. North America Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2016-2026)

Figure 44. North America Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2016-2026)

Figure 45. North America Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2016-2026)

Figure 46. United States Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Canada Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 48. Mexico Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 49. Europe Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2016-2026)

Figure 50. Europe Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2016-2026)

Figure 51. Europe Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2016-2026)

Figure 52. Germany Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. France Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. United Kingdom Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Russia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Italy Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2016-2026)

Figure 58. Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2016-2026)

Figure 59. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Market Share by Region (2016-2026)

Figure 60. China Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Japan Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. South Korea Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. India Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Southeast Asia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Australia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. South America Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2016-2026)

Figure 67. South America Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2016-2026)

Figure 68. South America Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2016-2026)

Figure 69. Brazil Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Argentina Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Middle East and Africa Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2016-2026)

Figure 72. Middle East and Africa Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2016-2026)

Figure 73. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2016-2026)

Figure 74. Turkey Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Saudi Arabia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. UAE Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 77. Methodology

Figure 78. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz